Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
64 hedge funds and large institutions have $30.5M invested in Lumos Pharma, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 25 reducing their positions, and 14 closing their positions.
87% more capital invested
Capital invested by funds: $16.3M → $30.5M (+$14.2M)
6% less funds holding
Funds holding: 68 → 64 (-4)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
59% less call options, than puts
Call options by funds: $579K | Put options by funds: $1.42M
80% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lion Point Capital
New York
|
+$4.94M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$125K |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
+$103K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$83.2K |
| 5 |
Morgan Stanley
New York
|
+$61.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$614K |
| 2 |
EP
Eversept Partners
New York
|
-$434K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$419K |
| 4 |
RCM
Requisite Capital Management
Dallas,
Texas
|
-$412K |
| 5 |
Millennium Management
New York
|
-$155K |
LUMO Hedge Fund Activity: Q4 2019 in Review
64 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2019, worth a combined $30.5M — up 87% from $16.3M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of LUMO and 10 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 5 added.
The largest buyer was Lion Point Capital, opening a new position worth an estimated $4.94M. The largest seller was Oxford Asset Management, cutting an estimated $614K.
- 64 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2019, down from 68 in Q3 2019.
- Funds reported $30.5M of Lumos Pharma, Inc. Common Stock stock for Q4 2019, up 87% quarter-over-quarter.
- 10 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2019 and 14 closed out, a net change of -4 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q4 2019 was Lion Point Capital, an estimated $4.94M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q4 2019 was Oxford Asset Management, an estimated $614K sold.
Based on aggregated 13F filings for Q4 2019.